Key facts
- It has raised $60.1M; the latest was Early Stage VC in Oct 2025.
- Notable investors include CDH Investments, Haiwang Capital, Heda Ventures, Y.R.Delta Fund, Huagai Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Innolake Biopharm
- ·The full record, as it builds
Funding rounds
No funding rounds for Innolake Biopharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innolake Biopharm
Developer of therapeutic drugs designed to overcome tumors and immune system diseases. The company offers research and development of therapeutic drugs and operates extensive product development pipelines, thereby enabling patients to receive better treatment and improve their health conditions.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- innolakebio.com/
- Ownership
- Privately Held (backing)
Innolake Biopharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innolake Biopharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innolake Biopharm in its N-PORT filings yet. We sweep new filings monthly.